Overview

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Phase:

PHASE2

Details

Lead Sponsor:

Syndeio Biosciences, Inc

Collaborator:

Worldwide Clinical Trials